Tags

Type your tag names separated by a space and hit enter

Aripiprazole: pharmacology, efficacy, safety and tolerability.
Expert Rev Neurother. 2005 May; 5(3):297-307.ER

Abstract

Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Aripiprazole is generally well tolerated relative to other antipsychotic medications, although commonly reported side effects include worsening extrapyramidal symptoms and motoric activation similar to akathisia. Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole.

Authors+Show Affiliations

Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Durham, NC 27710, USA. warren.kinghorn@duke.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15938662

Citation

Kinghorn, Warren A., and Joseph P. McEvoy. "Aripiprazole: Pharmacology, Efficacy, Safety and Tolerability." Expert Review of Neurotherapeutics, vol. 5, no. 3, 2005, pp. 297-307.
Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 2005;5(3):297-307.
Kinghorn, W. A., & McEvoy, J. P. (2005). Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Review of Neurotherapeutics, 5(3), 297-307.
Kinghorn WA, McEvoy JP. Aripiprazole: Pharmacology, Efficacy, Safety and Tolerability. Expert Rev Neurother. 2005;5(3):297-307. PubMed PMID: 15938662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole: pharmacology, efficacy, safety and tolerability. AU - Kinghorn,Warren A, AU - McEvoy,Joseph P, PY - 2005/6/9/pubmed PY - 2006/6/6/medline PY - 2005/6/9/entrez SP - 297 EP - 307 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 5 IS - 3 N2 - Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Aripiprazole is generally well tolerated relative to other antipsychotic medications, although commonly reported side effects include worsening extrapyramidal symptoms and motoric activation similar to akathisia. Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/15938662/Aripiprazole:_pharmacology_efficacy_safety_and_tolerability_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737175.5.3.297 DB - PRIME DP - Unbound Medicine ER -